Novel activating SNRNP70-ALK fusion in congenital infant-type hemispheric glioma displays clinical response to lorlatinib: a case-report

We report a child with an antenatally detected brain tumor that progressed over three years' time despite surgery, chemo- and proton therapy. Retrospective whole-genome and transcriptome sequencing with methylation analysis of primary tumor tissue led to the molecular diagnosis infant-type hemispheric glioma, and identified a novel SNRNP70::ALK fusion, providing a therapeutic target for compassionate-use precision treatment with the ALK tyrosine kinase inhibitor lorlatinib. Functional studies confirmed the fusion protein to be expressed and active in the patient's tumor. After two years of therapy, the child has sustained partial tumor regression on MRI and no new neurological symptoms. We conclude that comprehensive multi-omics analyses are required for correct molecular diagnosis in childhood CNS tumors and can radically impact patient outcome by identifying molecular targets for precision treatment.

Authors

Institutions

Publication Details

Journal
npj Precision Oncology
Published
2026-02-26
DOI
https://doi.org/10.1038/s41698-026-01336-x
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Novel activating SNRNP70-ALK fusion in congenital infant-type hemispheric glioma displays clinical response to lorlatinib: a case-report

Ruth H. Palmer, Richard W. Rosenquist, Blaž Oder, Jesper Eisfeldt et al.
npj Precision Oncology
Glioma Diagnosis and Treatment
article

Novel activating SNRNP70-ALK fusion in congenital infant-type hemispheric glioma displays clinical response to lorlatinib: a case-report

Ruth H. Palmer, Richard W. Rosenquist, Blaž Oder, Jesper Eisfeldt, Teresita Díaz de Ståhl, Johanna Sandgren, Kleopatra Georgantzi, Christopher Illies, Cecilia Arthur, Cecilia Jylhä, Daniel Hägerstrand, Ulrika Sandvik, J Svoboda, Gisela Barbany, Emma Tham, Bengt Hallberg, Jikui Guan
article en

Abstract

We report a child with an antenatally detected brain tumor that progressed over three years' time despite surgery, chemo- and proton therapy. Retrospective whole-genome and transcriptome sequencing with methylation analysis of primary tumor tissue led to the molecular diagnosis infant-type hemispheric glioma, and identified a novel SNRNP70::ALK fusion, providing a therapeutic target for compassionate-use precision treatment with the ALK tyrosine kinase inhibitor lorlatinib. Functional studies confirmed the fusion protein to be expressed and active in the patient's tumor. After two years of therapy, the child has sustained partial tumor regression on MRI and no new neurological symptoms. We conclude that comprehensive multi-omics analyses are required for correct molecular diagnosis in childhood CNS tumors and can radically impact patient outcome by identifying molecular targets for precision treatment.

npj Precision OncologyVol. 10(1)
Karolinska University Hospital (SE), Karolinska Institutet (SE), University of Gothenburg (SE)
Cancerfonden, Knut och Alice Wallenbergs Stiftelse, Vetenskapsrådet, Barncancerfonden, Science for Life Laboratory, Uppsala Multidisciplinary Center for Advanced Computational Science
Good health and well-being
Openalex Percentile: Top 42%
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.